Theravance Biopharma Inc TBPH

NAS: TBPH | ISIN: KYG8807B1068   29/04/2024
8,990 USD (-1,43%)
(-1,43%)   29/04/2024
Grafiek Theravance Biopharma Inc Grafiek Theravance Biopharma Inc

Theravance Biopharma Inc in het nieuws

29 april 2024 · Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024 · Persbericht

10 april 2024 · Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024 · Persbericht

26 februari 2024 · Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update · Persbericht

22 februari 2024 · Theravance Biopharma to Participate in an Upcoming Investor Conference · Persbericht

14 februari 2024 · Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024 · Persbericht

5 januari 2024 · Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) · Persbericht

21 december 2023 · Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors · Persbericht

18 december 2023 · Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference · Persbericht

13 november 2023 · Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) · Persbericht

7 november 2023 · Theravance Biopharma, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update · Persbericht

Profiel Theravance Biopharma Inc

Fabricage van farmaceutische preparaten
Farmaceutische producten: Andere
Gezondheidstechnologie
Productie

CEO: Rick Winningham

Werknemers: 270

Aandelen Theravance Biopharma Inc

Beurswaarde: 442,87 miljoen USD

Effecten: 48,56 miljoen

Winst per aandeel (12 maand):  PLUS

Beta: 0,29

Mijn selecties